L5 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:300304 CAPLUS Full-text
DN 142:367688
TI Use of galanthamine and the derivatives thereof in the production of medicaments for the treatment of postoperative delirium
IN Bodenteich, Angelika; Frantsits, Werner J.; Pirich, Eberhard; Czollner, Laszlo
PA Sanochemia Pharmazeutika A.-G., Austria
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005030332	A2	20050407	WO 2004-AT251	20040712
	WO 2005030332	A3	20050602		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2506282	AA	20050407	CA 2004-2506282	20040712
	NO 2005002177	A	20050624	NO 2005-2177	20050503
PRAI	AT 2003-1538	A	20030929		
	WO 2004-AT251	W	20040712		

OS MARPAT 142:367688
AB The invention discloses the use of galanthamine and the cholinergically active derivs. thereof in the production of medicaments for preventive treatment of postoperative delirium and/or subsyndronal postoperative delirium. Galanthamine, the galanthamine derivative(4aS,6R,8aS)-6-hydroxy-3- methoxy-11-methyl-4a,5,9,10-tetrahydro-6H-benzofuro[3a,3,2-ef] [2]benzazepinium bromide, and analogous salts, hydrates or solvates are suited for use according to the invention.
IT **198988-69-1 273749-93-2 273749-95-4**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(galanthamine and galanthamine derivs. for treatment of postoperative delirium)
RN 198988-69-1 CAPLUS
CN 3H,6H-5,10b-Ethanophenanthridin-3-one, 7-bromo-4,4a-dihydro-10-hydroxy-9-methoxy- (9CI) (CA INDEX NAME)



RN 273749-93-2 CAPLUS
CN 3H,6H-5,10b-Ethanophenanthridine-3,10-diol, 7-bromo-4,4a-dihydro-9-methoxy-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273749-95-4 CAPLUS
CN 3H,6H-5,10b-Ethanophenanthridine-3,10-diol, 7-bromo-1,2,4,4a-tetrahydro-9-methoxy- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:61759 CAPLUS Full-text
DN 138:369041
TI Seco-isopowellaminone: a new heterocycle from nornarwedine
AU Hirnschall, Manfred; Mereiter, Kurt; Froehlich, Johannes; Jordis, Ulrich
CS Institute of Applied Synthetic Chemistry, Vienna, 1060, Austria
SO Journal of Heterocyclic Chemistry (2002), 39(6), 1265-1270
CODEN: JHTCAD; ISSN: 0022-152X
PB HeteroCorporation
DT Journal
LA English
OS CASREACT 138:369041
AB It is known that nornarwedine-type mols. can be converted into crinine-type compds. by a reverse Michael- / Michael addition Narwedine and bromonarwedine yield, as confirmed by X-ray structure determination, the known seco-powellaminone as well as the novel seco-isopowellaminone.
IT **406673-87-8P 522655-29-4P 522655-31-8P**
522655-35-2P 522655-39-6P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of seco-powellaminone as well as the novel seco-isopowellaminone from narwedine and bromonarwedine via a reverse Michael- / Michael addition)
RN 406673-87-8 CAPLUS
CN 3H,6H-5,10b-Ethanophenanthridin-3-one, 7-bromo-4,4a-dihydro-10-hydroxy-9-methoxy-, (4aR,5S,10bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 522655-29-4 CAPLUS
CN 3H,6H-5,10b-Ethanophenanthridin-3-one, 4,4a-dihydro-10-hydroxy-9-methoxy-, (4aR,5S,10bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 522655-31-8 CAPLUS
CN 3H,6H-5,10b-Ethanophenanthridin-3-one, 4,4a-dihydro-10-hydroxy-9-methoxy-, (4aR,5R,10bR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 522655-35-2 CAPLUS
CN 3H,6H-5,10b-Ethanophenanthridin-3-one, 7-bromo-4,4a-dihydro-10-hydroxy-9-methoxy-, (4aR,5R,10bR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 522655-39-6 CAPLUS
CN 3H,6H-5,10b-Ethanophenanthridin-3-one, 7-bromo-4,4a-dihydro-10-hydroxy-9-methoxy-, hydrochloride, (4aR,5S,10bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:33226 CAPLUS Full-text
DN 136:279595
TI Bidirectional conversion of galanthamine and crinine type heterocycles
AU Treu, Matthias; Welzig, Stefan; Jordis, Ulrich
CS Department of Organic Chemistry, Vienna University of Technology, Vienna, A-1060, Austria
SO Heterocycles (2001), 55(12), 2397-2404
CODEN: HTCYAM; ISSN: 0385-5414
PB Japan Institute of Heterocyclic Chemistry
DT Journal
LA English
OS CASREACT 136:279595
AB The conversion of galanthamine-type mols. into crinine-type compds. and vice versa has been accomplished by a ring opening-Michael addition-cascade of a galanthamine-type secondary amine and a crinine-type quaternary ammonium salt. One crinine analog exhibited the same BChE activity as galanthamine without any AChe inhibition.
IT **406673-85-6P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(bidirectional conversion of galanthamine and crinine type heterocycles)
RN 406673-85-6 CAPLUS
CN 3H,6H-5,10b-Ethanophenanthridine-3,10-diol, 7-bromo-4,4a-dihydro-9-methoxy-, (3R,4aS,5R,10bR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **406673-88-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(bidirectional conversion of galanthamine and crinine type heterocycles)
RN 406673-88-9 CAPLUS
CN 3H,6H-5,10b-Ethanophenanthridine-3,10-diol, 4,4a-dihydro-9-methoxy-, (3R,4aS,5R,10bR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **406673-87-8P 406673-92-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(bidirectional conversion of galanthamine and crinine type heterocycles)

RN 406673-87-8 CAPLUS

CN 3H,6H-5,10b-Ethanophenanthridin-3-one, 7-bromo-4,4a-dihydro-10-hydroxy-9-methoxy-, (4aR,5S,10bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 406673-92-5 CAPLUS

CN 3H,6H-5,10b-Ethanophenanthridinium, 7-bromo-4,4a-dihydro-10-hydroxy-9-methoxy-5-methyl-3-oxo-, iodide, (4aR,5S,10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:383937 CAPLUS Full-text
DN 133:26864
TI Use of galanthamine and galanthamine derivatives for the treatment of acute functional brain damage
IN Mucke, Martin Alois Hermann; Frohlich, Johannes; Jordis, Ulrich
PA Sanochemia Pharmazeutika A.-G., Austria
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000032199	A1	20000608	WO 1998-AT291	19981201
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9914300	A1	20000619	AU 1999-14300	19981201
PRAI WO 1998-AT291	A	19981201		

AB The invention relates to the use of galanthamine and analogs or acidic addition salts thereof in the production of medicaments for treating states arising from cerebrovascular accidents or closed focal craniocerebral traumas or whiplash injuries.

IT **198988-69-1 273749-93-2 273749-94-3 273749-95-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(galanthamine and derivs. for treatment of acute functional brain damage)

RN 198988-69-1 CAPLUS
CN 3H,6H-5,10b-Ethanophenanthridin-3-one, 7-bromo-4,4a-dihydro-10-hydroxy-9-methoxy- (9CI) (CA INDEX NAME)



RN 273749-93-2 CAPLUS
CN 3H,6H-5,10b-Ethanophenanthridine-3,10-diol, 7-bromo-4,4a-dihydro-9-methoxy-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 273749-94-3 CAPLUS
CN 3H,6H-5,10b-Ethanophenanthridine-3,10-diol, 4,4a-dihydro-9-methoxy- (9CI) (CA INDEX NAME)



RN 273749-95-4 CAPLUS
CN 3H,6H-5,10b-Ethanophenanthridine-3,10-diol, 7-bromo-1,2,4,4a-tetrahydro-9-methoxy- (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

Appl's

L5 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:717921 CAPLUS Full-text
DN 128:13368
TI New benzazepine derivatives, medicaments containing the same and their use to prepare medicaments
IN Czollner, Laszlo; Frohlich, Johannes; Jordis, Ulrich; Kuenburg, Bernhard
PA Sanochemia Ltd., Malta
SO PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9740049	A1	19971030	WO 1997-AT74	19970421
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AT 9600716	A	19971015	AT 1996-716	19960419
	AT 403803	B	19980525		
	AU 9724985	A1	19971112	AU 1997-24985	19970421
	EP 897387	A1	19990224	EP 1997-916263	19970421
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, FI				
	PL 189834	B1	20050930	PL 1997-329411	19970421
	RO 120136	B1	20050930	RO 1998-1487	19970421
	PL 190032	B1	20051031	PL 1997-361697	19970421
	TW 224595	B1	20041201	TW 1997-86106195	19970509
	BG 64560	B1	20050729	BG 1998-102836	19981012
	NO 9804852	A	19981116	NO 1998-4852	19981016
	US 2003092700	A1	20030515	US 1999-242339	19990211
	US 6638925	B2	20031028		
	US 2004067974	A1	20040408	US 2003-647283	20030826
PRAI	AT 1996-716	A	19960419		
	WO 1997-AT74	W	19970421		
	US 1999-242339	A3	19990211		

OS MARPAT 128:13368
GI



I



II

AB The synthesis of benzofuro[3a,3,2,ef][2]benzazepines (I) [R1,R2 = H, halo, CN, NC, OH, SH, SO3H, NH2, CF3, (un)substituted alkyl, (un)substituted alkoxy, (un)substituted aryl, (un)substituted aryloxy; R3 = OH, OMe; R4,R5 = H2, O, substituted O, (un)substituted alkyl, (un)substituted aryl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted hydrazone, (un)substituted oxime; X = H2, O] and diazabicyclo[2.2.1]heptanes (II) [R8 = CH2Ph, 4-MeC6H4SO2, H, (un)substituted alkyl, Me3CO2C; R9 = (un)substituted Ph, CH2Ph, CHPh2, Me3CO2C] are described. Thus, I (R1 = Br, R2 = H, R3 = OMe, R4 = OH,

R5 = H, R6 = H, X = H2) (III) was prepared by tartrate resolution of (±)-N-demethyl-8-bromogalanthamine. III in in vitro study showed an IC50 of >150 in umol for the inhibition of acetylcholine esterase. Also disclosed are medicaments which contain compds. of formulas (I) and/or (II) and may be successfully used for treating Alzheimer disease and related demential states, as well as the Langdon-Down syndrome.

IT **198988-69-1P 198988-70-4P 198988-72-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzazepine galanthamine analogs and diazabicycloheptanes for use in treatment of dementia)

RN 198988-69-1 CAPLUS

CN 3H,6H-5,10b-Ethanophenanthridin-3-one, 7-bromo-4,4a-dihydro-10-hydroxy-9-methoxy- (9CI) (CA INDEX NAME)



RN 198988-70-4 CAPLUS

CN 3H,6H-5,10b-Ethanophenanthridine-3,10-diol, 7-bromo-4,4a-dihydro-9-methoxy-, (3α,4aα,5α,10bα)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 198988-72-6 CAPLUS

CN 3H,6H-5,10b-Ethanophenanthridine-3,10-diol, 7-bromo-4,4a-dihydro-9-methoxy-, (3α,4aβ,5β,10bβ)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1986:618421 CAPLUS Full-text
DN 105:218421
TI Clastogenic effect of hippeastidine (HIPP) (1,2,3,4,4a,6-hexahydro-10-hydroxy-3,8,9-trimethoxy-5,10b-ethanophenanthridine)
AU Alarcon, M.; Cea, G.; Weigert, G.
CS Fac. Biol. Sci. Nat. Resour., Univ. Concepcion, Concepcion, Chile
SO Bulletin of Environmental Contamination and Toxicology (1986), 37(4), 508-12
CODEN: BECTA6; ISSN: 0007-4861
DT Journal
LA English
GI



I

AB In a screening of chilean plants for anticancer activity, a number of alkaloids were isolated from Hippeastrum ananuca (Amaryllidaceae). HIPP (I) [**66276-51-5**] is the 1 that has been shown to exhibit the major antineoplastic activity as tested in KB cells (a human transformed nasopharyngeal cell line) showing an ED50 = 0.270 μg/mL, the dosage required to inhibit by 50% the growth of a cell population.

IT **66276-51-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antineoplastic activity of, in KB cells)
RN 66276-51-5 CAPLUS
CN 1H,6H-5,10b-Ethanophenanthridin-10-ol, 2,3,4,4a-tetrahydro-3,8,9-trimethoxy-, [3R-(3α,4aβ,5α,10bα)]- (9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1982:527844 CAPLUS Full-text
DN 97:127844
TI Hippeastidine, C17H23O4N
AU Watson, William H.; Zabel, Volker; Silva, Mario; Pacheco, Patricia
CS Dep. Chem., Texas Christian Univ., Fort Worth, TX, 76129, USA
SO Crystal Structure Communications (1982), 11(1), 157-62
CODEN: CSCMCS; ISSN: 0302-1742
DT Journal
LA English
AB The crystal structure of hippeastidine (1,2,3,4,4a,6-hexahydro-10-hydroxy-3,8,9-trimethoxy-5,10b-ethanophenanthridine) was determined the ring conformations were described.
IT **81904-08-7**
RL: PRP (Properties)
(crystal structure of)
RN 81904-08-7 CAPLUS
CN 1H,6H-5,10b-Ethanophenanthridine-3,10-diol, 2,3,4,4a-tetrahydro-8,9-dimethoxy-, [3R-(3α,4aβ,5α,10bα)]- (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1982:214311 CAPLUS Full-text
DN 96:214311
TI Chemical study of Chilean Amaryllidaceae. II. New alkaloids from Hippeastrum ananuca Phil
AU Pacheco, Patricia Del C.; Silva, Mario J.; Sammes, Peter G.; Watson, William H.
CS Fac. Cienc. Biol. Recursos Nat., Univ. Concepcion, Concepcion, Chile
SO Boletin de la Sociedad Chilena de Quimica (1982), 27(2), 289-90
CODEN: BOCQAX; ISSN: 0366-1644
DT Journal
LA Spanish
GI



I

AB I, m. 175°, and hemanthamine, m. 205°, were isolated from H. ananuca bulbs, and identified by UV, IR, and H+-NMR spectroscopy.
IT **81904-08-7**
RL: BIOL (Biological study)
(of Hippeastrum ananuca bulb)
RN 81904-08-7 CAPLUS
CN 1H,6H-5,10b-Ethanophenanthridine-3,10-diol, 2,3,4,4a-tetrahydro-8,9-dimethoxy-, [3R-(3α,4aβ,5α,10bα)]- (9CI) (CA INDEX NAME)



L5 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1978:503746 CAPLUS Full-text
DN 89:103746
TI Alkaloids of Chilean Amaryllidaceae. I. Hippeastidine and epi-homolycorine, two novel alkaloids
AU Pacheco, P.; Silva, M.; Steglich, W.; Watson, W. H.
CS Dep. Bot., Univ. Concepcion, Concepcion, Chile
SO Revista Latinoamericana de Quimica (1978), 9(1), 28-32 Published in: Rev. Latinoamer. Quim. 8(4)
CODEN: RLAQA8; ISSN: 0370-5943
DT Journal
LA English
GI



I



II

AB Lycorine, homolycorine, maritidine, hippeastidine (I), and epihomolycorine (II) were isolated from Hippeastrum ananuca bulbs. The total alkaloid extract was separated into 4 fractions, each of which showed antitumor activity in KB assay. The structures of I and II were assigned from spectral and x-ray diffraction data.

IT **66276-51-5**
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(of Hippeastrum ananuca)
RN 66276-51-5 CAPLUS
CN 1H,6H-5,10b-Ethanophenanthridin-10-ol, 2,3,4,4a-tetrahydro-3,8,9-trimethoxy-, [3R-(3α,4aβ,5α,10bα)]- (9CI) (CA INDEX NAME)



IT **66322-24-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)(preparation of)
RN 66322-24-5 CAPLUS
CN 1H,6H-5,10b-Ethanophenanthridin-10-ol, 2,3,4,4a-tetrahydro-3,8,9-trimethoxy-, [3R-(3α,4aβ,5α,10bα)]-, compd. with 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 66276-51-5
CMF C18 H25 N O4



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



L5 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1978:136819 CAPLUS Full-text
DN 88:136819
TI 1,2,3,4,4a,6-Hexahydro-10-hydroxy-3,8,9-trimethoxy-5,10b-ethanophenanthridinium picrate
AU Watson, William H.; Taira, Zenei; Silva, Mario; Pacheco, Patricia
CS Dep. Chem., Texas Christian Univ., Fort Worth, TX, USA
SO Crystal Structure Communications (1977), 6(4), 797-801
CODEN: CSCMCS; ISSN: 0302-1742
DT Journal
LA English
AB The crystal structure of the title compound (hippeastidine picrate) was determined The conformation was discussed.
IT **66322-24-5**
RL: PRP (Properties)
(crystal structure of)
RN 66322-24-5 CAPLUS
CN 1H,6H-5,10b-Ethanophenanthridin-10-ol, 2,3,4,4a-tetrahydro-3,8,9-trimethoxy-, [3R-(3α,4aβ,5α,10bα)]-, compd. with 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 66276-51-5
CMF C18 H25 N O4



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



IT **66276-51-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 66276-51-5 CAPLUS
CN 1H,6H-5,10b-Ethanophenanthridin-10-ol, 2,3,4,4a-tetrahydro-3,8,9-trimethoxy-, [3R-(3α,4aβ,5α,10bα)]- (9CI) (CA INDEX NAME)



L8 ANSWER 1 OF 1 MARPAT COPYRIGHT 2006 ACS on STN
AN 132:35555 MARPAT Full-text
TI Biomimetic combinatorial synthesis of polycyclic natural products
IN Lindsley, Craig W.; Chen, Chuo; Shair, Matthew D.; Westwood, Nicholas J.; Chan, Lawrence K.; Pelish, Henry Efram; Sheehan, Scott M.; Goess, Brian C.; Layton, Mark E.
PA President and Fellows of Harvard College, USA
SO PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9964379	A2	19991216	WO 1999-US12942	19990611
WO 9964379	A3	20000803		

W: CA, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRAI US 1998-89124P 19980611
US 1999-329970 19990610
GI


I


II


III

AB The present invention provides biomimetic compds. and libraries thereof, as well as methods for their production In general, the inventive method involves the selection of a desired biol. synthetic pathway and mimics that synthetic pathway utilizing modern synthetic tools. The structures formed from this method are preferably generated in fewer than four steps. These scaffold structures can than be functionalized to yield biomimetic compds. and libraries of compds. In preferred embodiments, biomimetic compds. and libraries are generated from an oxidative phenolic (I) [R1, R2, R4, R5 = (un)substituted alkyl, (un)substituted alkenyl, (un)substituted aminoalkyl, (un)substituted acylamino, (un)substituted acyloxy, (un)substituted alkoxycarbonyl, (un)substituted alkoxy, (un)substituted alkylaryl, (un)substituted thioalkyl, acyl, amino, OH, SH, aryloxy, arylalkoxy, H, alkynyl, halogen, CN, CONH2, NO2, CF3, (un)substituted heterocyclyl; R3 = electron withdrawing group; R2,R3,R4,R5 taken together form a carbocycle or heterocycle having 3 to 10 atoms in the ring] coupling reaction yielding (II) [R6, R7, R9, R10 as defined for R1, R2, R4, R5; R8 = electron withdrawing group; R7, R8, R9 taken together form a carbocycle or heterocycle having 3 to 10 atoms in the ring]. In other particularly preferred embodiments, the compds. and libraries of compds. are generated from cascade reactions to yield bicyclo [n.3.1] ring systems (III) [R to R11 as defined for R1, R2, R4, R5 above; R to R11 taken together form a carbocycle or heterocycle having 3 to 10 atoms in the ring; n = 0-3], medium ring systems, and fused ring systems. In

addition to compds., libraries and methods for their production, the present invention also provides pharmaceutical compns. and methods and kits for determining one or more biol. activities of the library members.

MSTR 5



G1 = OH
G11 = N
Patent location: claim 12
Note: ring formation also claimed

```
=> d l2; d his; log y
L2 HAS NO ANSWERS
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L2                QUE  ABB=ON   PLU=ON   L1


     (FILE 'HOME' ENTERED AT 08:06:06 ON 29 MAR 2006)

     FILE 'REGISTRY' ENTERED AT 08:06:17 ON 29 MAR 2006
L1                STRUCTURE UPLOADED
L2                QUE L1
L3              3 S L2
L4             18 S L2 FUL

     FILE 'CAPLUS' ENTERED AT 08:06:38 ON 29 MAR 2006
L5             10 S L4

     FILE 'MARPAT' ENTERED AT 08:07:06 ON 29 MAR 2006
L6              0 S L2
L7              3 S L2 FUL
L8              1 S L7 NOT L5


COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               122.17     340.88

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -0.71      -8.21

STN INTERNATIONAL LOGOFF AT 08:07:39 ON 29 MAR 2006
```